Tag: Humacyte

Humacyte to present long-term follow-up data from Phase 2 vascular access...

Humacyte has announced that the clinical results of five-year outcomes in patients receiving the human acellular vessels (HAV) for arteriovenous (AV) access in haemodialysis...

Humacyte commences phase II vascular trauma trial

Humacyte has announced the initiation of a US phase II vascular trauma clinical trial of Humacyl, its investigational human acellular vessel, for vascular replacement...

Humacyte appoints Jeffrey Lawson as president and CEO

Humacyte, an innovator in biotechnology and regenerative medicine, has announced that Jeffrey Lawson has been appointed president and chief executive officer. The former chairman...